There is limited evidence of tobacco smoking's effect on cancer survivors' quality of life (QOL) and function. As the natural history of localized prostate cancer (PCa) is protracted, there is a need to identify modifiable risk factors that can influence PCa survivorship, such as tobacco smoking.
We used up to 10-year survey data from the CEASAR (Comparative Effectiveness Analysis of Surgery and Radiation) study, a prospective, population-based, observational study of patients diagnosed with localized PCa in 2011-2012. Survivors were categorized as never, former, and current smokers during survivorship. Adjusted multivariable linear regression models were used to assess the association between smoking and 5-year and 10-year scores on the 26-Item Expanded Prostate Index Composite (EPIC-26; PCa-specific domains) and 5-year scores on the Medical Outcomes Study 36-Item Short Form Survey (SF-36; general health domains).
We included 2426 patients of whom 142 (6%) were current smokers, 1039 (43%) were former smokers, and 1245 (51%) were never smokers. Current smokers were more likely to be Black, low-income, and less formally educated (all p < 0.01). After adjustments, there was no association between smoking history with disease-specific functional outcomes (EPIC-26) at 5 years or 10 years (all p > 0.05). However, in adjusted analyses assessing general health domains (SF-36), compared to participants who never smoked, current smokers during survivorship had worse physical function (- 10.96, 95% CI - 16.37 to - 5.55, p < 0.01) at 5 years.
PCa survivors who continue to smoke experience worse physical functioning though there is no significant independent effect on PCa-specific functional domains.
Prostate cancer survivors who continue to smoke experience worse physical functioning though there is no significant independent effect on PCa-specific functional domains. Smoking cessation may improve prostate cancer survivorship.
Journal of cancer survivorship : research and practice. 2024 Oct 14 [Epub ahead of print]
David-Dan Nguyen, Daniel A Barocas, Zhiguo Zhao, Li-Ching Huang, Tatsuki Koyama, Bashir Al Hussein Ai Awamlh, David F Penson, Alicia K Morgans, Michael Goodman, Ann S Hamilton, Xia-Cheng Wu, Jie Li, Lisa E Paddock, Antoinette M Stroup, Brock B O'Neil, Karen E Hoffman, Christopher J D Wallis
Division of Urology, Department of Surgery, University of Toronto, Toronto, ON, Canada., Department of Urology, Vanderbilt University Medical Center, Nashville, TN, USA., Department of Biostatistics, Vanderbilt University Medical Center, Nashville, TN, USA., Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Department of Epidemiology, Emory University Rollins School of Public Health, Atlanta, GA, USA., Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA., Epidemiology and Population Health, Louisiana State University Health Sciences Center, New Orleans, LA, USA., Rutgers Cancer Institute of New Jersey, New Brunswick, NJ and New Jersey State Cancer Registry, Cancer Epidemiology Services, New Jersey Department of Health, New Brunswick, NJ, USA., Department of Urology, University of Utah Health, Salt Lake City, UT, USA., Department of Radiation Oncology, The University of Texas MD Anderson Center, Houston, TX, USA., Division of Urology, Department of Surgery, University of Toronto, Toronto, ON, Canada. .